The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
PUBLICATIONS
FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer
San Antonio Breast Cancer Symposium
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone
Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
